Bioxyne (ASX:BXN) received commitments to raise AU$3 million via the placing of 120 million new shares at AU$0.025 apiece, according to a Friday Australian bourse filing.
It will also issue 60 million options on the basis of one option for every two new shares, with an exercise price of AU$0.05 and an expiry date of two years from the date of issue.
It will use the proceeds to support its expansion into European markets as well as the establishment and certification of medical cannabis manufacturing facilities in the UK and Czechia.
Its directors will participate in the amount of AU$110,000, subject to shareholder approval.
Alpine Capital was the sole lead manager and book runner to the placement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.